Compare Ares Capital Corporation (ARCC) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs Inovio Pharmaceuticals Inc — how do they compare? Ares Capital Corporation trades at $19.86 (market cap $14.34B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Ares Capital Corporation is far larger — about 182.6× Inovio Pharmaceuticals Inc's market cap, and Ares Capital Corporation pays a 9.61% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ARCC | INO | |
|---|---|---|
Market Cap | $14.34B | $78.55M |
Sector | Financials | Health |
52-Week High | $22.68 | $2.87 |
52-Week Low | $17.45 | $0.66 |
Dividend Yield | 9.61% | — |
Enterprise Value | — | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARCC trades at $19.875, down 0.53% on the day, with strong analyst support showing 24 buy ratings and a consensus price target of $19.63. The stock maintains a bullish technical signal with moving averages supporting upward momentum, though oscillators indicate some near-term pressure. Recent earnings showed Q2 2026 EPS of $0.47, slightly below expectations, while the company continues its 17-year dividend streak with consistent $0.48 quarterly payments.
The outlook remains positive with solid fundamentals including 81.77% net income margin and 6.88% ROE, though investors should monitor declining revenue trends from $1.7B in 2024 to projected $1.2B in 2026. Key risks include private credit market strain and dividend coverage tightening to 104%, while institutional confidence remains high with no sell ratings among 32 analysts covering the stock.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
